Late-stage CKD-induced comorbidity therapeutics market to reach $10.5 bn by 2026
One of the most prominent clinical issues surrounding the HPT, HP, and HK space is patient compliance with current therapy options
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Category
Management
Majority of oncology clinical trials in China failed to meet enrolment targets
Enrolment efficiencies of 324 clinical trials were conducted between January 1, 2012 and December 31, 2017
A sustainable future with green chemistry
Nitesh H Mehta, Co-Founder Director, Newreka Green-Synth Technologies and Krishna B Padia, Executive Director, Green ChemisTree…
CDSS market in India to reach 206.1 million dollars
According to the new BIS Research report, the spread of this technology to other markets and geographies in India will be driven…
Melanoma sales projected to rise to $5.5 bn dollars in 2026
According to GlobalData, there will be nearly 207,000 cases of melanoma in 2026, rising from nearly 166,000 in 2016
Global glaucoma market to reach $3.8 bn by 2026
The growth will be driven by the launch of pipeline products
Legal aspects to maintain quality standard of drugs
Rajdutt Shekhar Singh, Partner, Singh & Associates, talks on the laws governing the pharma sector and recent intitiatives to…
Union Budget 2018 Will it please the pharma sector?
This budget would be the last full-fledged budget of the Narendra Modi-led government before 2019 elections and like other…
The US FDA approval of Trastuzumab is a huge milestone for Biocon
First biosimilar Trastuzumab has been recently approved by the US FDA. Kiran Mazumdar Shaw, CMD, Biocon, reveals more an in an…
Can Indian Pharma Inc find its lost mojo?
Ashish Prasad, Partner, Economic Laws Practice, Indian Pharma Inc will need to take stock of the current situation and chalk out a…
Policy experiences of 2017 for pharma sector
Krishna Sarma, Managing Partner of Corporate Law Group, gives an insight about the need to take positive learnings from the…
Towards a healthier Bharat
As Novartis’ social business venture, Arogya Parivar completes a decade, the company prepares to plug the gaps and scale up both…
Is it too early to talk of global health?
Global ill-health can render even health-secure nations vulnerable in a seamless world. An insight by Bharathi Ghanashyam, Founder…
The global negative pressure wound therapy market set to reach $1.3 bn in 2024
According to GlobalData, NPWT market growth will be driven primarily by increasing awareness of the technique and its various…
Crohn’s Disease diagnosed incident cases set to increase in the 7MM to 2026
The burden of diagnosed Crohn’s Disease (CD) is expected to grow between 2016 and 2026 in the seven major markets
Affluent market, medical tourism to steer best-in line drug delivery devices in India
Trends indicate that medical tourism will also bolster the demand for sophisticated devices and emerge as an important source of…
New diabetes therapeutics to steal ground from insulin therapies: GBI Research
Increased market diversification is expected due to patent expiries for major insulin products
Consolidated FDI policy 2017 – Implications on pharmaceuticals and healthcare sector
Rabindra Jhunjhunwala, Partner, Khaitan & Co and Sameer Sah, Associate Partner, Khaitan & Co share their insights on…
Type II diabetes market in South-East Asia set to experience strong growth
According to GBI Research, the type II diabetes market will hit $2.9 billion by 2023
Osteoarthritis 7MM market set to be worth $3.5 bn by 2026
The OA pipeline is rapidly evolving due to improved understanding of the disease’s pathophysiology and recent biomarker…